Literatur
-
1
Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Hepatology.
1999;
29
1690-1697
-
2
Arroyo V, Gines P, Gerbes A L, Dudley F, Gentilini P, Laffi G, Reynolds T B, Ring-Larsen H, Schölmerich J.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
Hepatology.
1996;
23
164-176
-
3
Brensing K A, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr H U, Kramer H J, Spengler U, Schild H, Sauerbruch T.
Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.
Gut.
2000;
47
288-295
-
4
Christidis C, Mal F, Ramos J. et al .
Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions.
J Hepatol.
2001;
35
726-732
-
5
Gerbes A L, Gülberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. and the VPA study group .
Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist - a randomized controlled multicenter trial.
Gastroenterology.
2003;
in press
-
6
Ginès A, Escorsell A, Ginès P. et al .
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.
Gastroenterology.
1993;
105
229-236
-
7
Gines A, Fernandez-Esparrach G, Monescillo A. et al .
Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis.
Gastroenterology.
1996;
111
1002-1010
-
8
Ginès P, Arroyo V.
Hepatorenal syndrome.
J Am Soc Nephrol.
1999;
10
1833-1839
-
9
Gines P, Tito L, Arroyo V. et al .
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
Gastroenterology.
1988;
94
1493-1502
-
10
Gonwa T A, Klintmalm G B, Levy M, Jennings L S, Goldstein R M, Husberg B S.
Impact of pretransplant renal function on survival after liver transplantation.
Transplantation.
1995;
59
361-365
-
11
Gülberg V, Bilzer M, Gerbes A L.
Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Hepatology.
1999;
30
870-875
-
12
Gülberg V, Gerbes A L.
Diagnostik und Therapie des Aszites bei Leberzirrhose.
Internist (Berl.).
1998;
39
254-262
-
13
Gülberg V, Gerbes A L.
TIPS or Vasoconstrictors for the Treatment of Hepatorenal Syndrome Type 1 - Effect on Survival?.
Z Gastroenterol.
2002;
40
823-826
-
14
Jimenez W, Serradeil-Le Gal C, Ros J, Carmen C, Rivera F, Arroyo V.
Aquaretic efficacy of the V2-vasopressin (AVP) receptor antagonist SR 121 463 in cirrhotic rats with ascites.
Hepatology.
1999;
30
232A
-
15
Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes A L.
Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor.
Gastroenterology.
1991;
101
1060-1067
-
16 Møller S, Henriksen J H. The systemic circulation in cirrhosis. London: Blackwell In Arroyo V, Gines P, Rodes J, Schrier RW (eds.). Ascites and renal dysfunction in liver disease 1999: 307-329
-
17
Moreau R, Durand F, Poynard T. et al .
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
Gastroenterology.
2002;
122
923-930
-
18
Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J.
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology.
1988;
8
1151-1157
-
19
Sort P, Navasa M, Arroyo V. et al .
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med.
1999;
341
403-409
-
20
Tito L, Gines P, Arroyo V. et al .
Total paracentesis with intravenous albumin management of patients with cirrhosis and ascites.
Gastroenterology.
1990;
98
146-151
-
21
Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J M, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
J Hepatol.
2000;
33
43-48
Prof. Dr. A. L. Gerbes
Medizinische Klinik II, Klinikum der Ludwig-Maximilians-Universität München-Großhadern
Marchioninistraße 15
81377 München
Fax: 089/70952392
Email: gerbes@med2.med.uni-muenchen.de
